{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:10:44Z","timestamp":1793949044692,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-109-PP- 18"],"award-info":[{"award-number":["CA-109-PP- 18"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The incidence of neuroendocrine tumors (NETs) has been increasing in recent decades. Previously, we reported the incidence and survival of NETs in Taiwan by analyzing the 1996\u20132008 data from the Taiwan Cancer Registry. Here we performed an updated analysis on the incidence and survival of NETs in Taiwan from 1996 to 2015. The incidence of NETs was 0.244 per 100,000 in 1996 and increased to 3.162 per 100,000 in 2015. The most common site of NETs was rectum (29.65%), followed by lung\/bronchus (17.22%), and pancreas (10.71%). The 5- and 10-year overall survival rates of all NETs were 54.6% and 45.3%, respectively. Female and younger NETs patients had a better survival. The survival of all NETs diagnosed between 2010 and 2015 was better than those diagnosed between 2004 and 2009. Among the common sites of NETs, an improved survival of pancreatic NETs diagnosed between 2010 and 2015 compared to those diagnosed between 2004 and 2009 was observed. Overall, the incidence of NETs in Taiwan has continued to increase. The survival of pancreatic NET has shown a recent improvement. The development of novel therapeutic agents has the potential to improve the prognosis of NETs of other sites in the near future.<\/jats:p>","DOI":"10.1038\/s41598-021-86839-2","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T10:09:07Z","timestamp":1618222147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan"],"prefix":"10.1038","volume":"11","author":[{"given":"Jeffrey S.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Rong","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"86839_CR1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao, J. C. et al. One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063\u20133072 (2008).","journal-title":"J. Clin. Oncol."},{"key":"86839_CR2","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1002\/cncr.23883","volume":"113","author":"O Hauso","year":"2008","unstructured":"Hauso, O. et al. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 113, 2655\u20132664 (2008).","journal-title":"Cancer"},{"key":"86839_CR3","doi-asserted-by":"publisher","first-page":"e62487","DOI":"10.1371\/journal.pone.0062487","volume":"8","author":"HJ Tsai","year":"2013","unstructured":"Tsai, H. J. et al. The epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based study. PLoS ONE 8, e62487 (2013).","journal-title":"PLoS ONE"},{"key":"86839_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335\u20131342 (2017).","journal-title":"JAMA Oncol."},{"key":"86839_CR5","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol. 27, 4656\u20134663 (2009).","journal-title":"J. Clin. Oncol."},{"key":"86839_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin, M. E. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224\u2013233 (2014).","journal-title":"N. Engl. J. Med."},{"key":"86839_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-14-0360","volume":"22","author":"M Cives","year":"2015","unstructured":"Cives, M. et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr. Relat. Cancer 22, 1\u20139 (2015).","journal-title":"Endocr. Relat. Cancer"},{"key":"86839_CR8","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.2147\/DDDT.S84177","volume":"9","author":"EM Wolin","year":"2015","unstructured":"Wolin, E. M. et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des. Dev. Ther. 9, 5075\u20135086 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"86839_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514\u2013523 (2011).","journal-title":"N. Engl. J. Med."},{"key":"86839_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501\u2013513 (2011).","journal-title":"N. Engl. J. Med."},{"key":"86839_CR11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet 387, 968\u2013977 (2016).","journal-title":"Lancet"},{"key":"86839_CR12","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander, T. et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23, 4617\u20134624 (2017).","journal-title":"Clin. Cancer Res."},{"key":"86839_CR13","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom, D. J. et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 23, 2754\u20132762 (2005).","journal-title":"J. Clin. Oncol."},{"key":"86839_CR14","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1002\/cam4.1795","volume":"7","author":"JS Chang","year":"2018","unstructured":"Chang, J. S. et al. The incidence and survival of pancreatic cancer by histology, including rare subtypes: A nation-wide cancer registry-based study from Taiwan. Cancer Med. 7, 5775\u20135788 (2018).","journal-title":"Cancer Med."},{"key":"86839_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/MPA.0000000000000234","volume":"43","author":"TR Halfdanarson","year":"2014","unstructured":"Halfdanarson, T. R. et al. Risk factors for pancreatic neuroendocrine tumors: A clinic-based case-control study. Pancreas 43, 1219\u20131222 (2014).","journal-title":"Pancreas"},{"key":"86839_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000375164","volume":"101","author":"SP Haugvik","year":"2015","unstructured":"Haugvik, S. P. et al. Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: A systematic review and meta-analysis. Neuroendocrinology 101, 133\u2013142 (2015).","journal-title":"Neuroendocrinology"},{"key":"86839_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ijc.23529","volume":"123","author":"MM Hassan","year":"2008","unstructured":"Hassan, M. M. et al. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int. J. Cancer 123, 867\u2013873 (2008).","journal-title":"Int. J. Cancer"},{"key":"86839_CR18","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R","volume":"92","author":"K Hemminki","year":"2001","unstructured":"Hemminki, K. & Li, X. Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 92, 2204\u20132210 (2001).","journal-title":"Cancer"},{"key":"86839_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/00365521.2017.1310290","volume":"52","author":"SP Haugvik","year":"2017","unstructured":"Haugvik, S. P. et al. Smoking, alcohol and family history of cancer as risk factors for small intestinal neuroendocrine tumors: A systematic review and meta-analysis. Scand. J. Gastroenterol. 52, 797\u2013802 (2017).","journal-title":"Scand. J. Gastroenterol."},{"key":"86839_CR20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s10552-013-0251-8","volume":"24","author":"AJ Cross","year":"2013","unstructured":"Cross, A. J., Hollenbeck, A. R. & Park, Y. A large prospective study of risk factors for adenocarcinomas and malignant carcinoid tumors of the small intestine. Cancer Causes Control 24, 1737\u20131746 (2013).","journal-title":"Cancer Causes Control"},{"key":"86839_CR21","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1055-9965.EPI-14-0132","volume":"23","author":"YS Jung","year":"2014","unstructured":"Jung, Y. S. et al. Risk factors associated with rectal neuroendocrine tumors: A cross-sectional study. Cancer Epidemiol. Biomark. Prev. 23, 1406\u20131413 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"86839_CR22","doi-asserted-by":"publisher","first-page":"101598","DOI":"10.1016\/j.canep.2019.101598","volume":"63","author":"D Wyld","year":"2019","unstructured":"Wyld, D., Wan, M. H., Moore, J., Dunn, N. & Youl, P. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. Cancer Epidemiol. 63, 101598 (2019).","journal-title":"Cancer Epidemiol."},{"key":"86839_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet, J. et al. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121, 589\u2013597 (2015).","journal-title":"Cancer"},{"key":"86839_CR24","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.12659\/MSM.914541","volume":"25","author":"C Deng","year":"2019","unstructured":"Deng, C., Wu, S. G. & Tian, Y. Lung large cell neuroendocrine carcinoma: An analysis of patients from the surveillance, epidemiology, and end-results (SEER) database. Med. Sci. Monit. 25, 3636\u20133646 (2019).","journal-title":"Med. Sci. Monit."},{"key":"86839_CR25","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.7150\/jca.33367","volume":"10","author":"J Wang","year":"2019","unstructured":"Wang, J., Ye, L., Cai, H. & Jin, M. Comparative study of large cell neuroendocrine carcinoma and small cell lung carcinoma in high-grade neuroendocrine tumors of the lung: A large population-based study. J. Cancer 10, 4226\u20134236 (2019).","journal-title":"J. Cancer"},{"key":"86839_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","volume":"68","author":"CG Moertel","year":"1991","unstructured":"Moertel, C. G., Kvols, L. K., O\u2019Connell, M. J. & Rubin, J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68, 227\u2013232 (1991).","journal-title":"Cancer"},{"key":"86839_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry, E. et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer 81, 1351\u20131355 (1999).","journal-title":"Br. J. Cancer"},{"key":"86839_CR28","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","volume":"35","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study. J. Clin. Oncol. 35, 3823\u20133829 (2017).","journal-title":"J. Clin. Oncol."},{"key":"86839_CR29","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","volume":"23","author":"JE Gray","year":"2017","unstructured":"Gray, J. E. et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting trop-2, sacituzumab govitecan. Clin. Cancer Res. 23, 5711\u20135719 (2017).","journal-title":"Clin. Cancer Res."},{"key":"86839_CR30","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","volume":"18","author":"MC Pietanza","year":"2012","unstructured":"Pietanza, M. C. et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin. Cancer Res. 18, 1138\u20131145 (2012).","journal-title":"Clin. Cancer Res."},{"key":"86839_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin, C. M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 18, 42\u201351 (2017).","journal-title":"Lancet Oncol."},{"key":"86839_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","volume":"21","author":"RA Ramirez","year":"2016","unstructured":"Ramirez, R. A. et al. The role of capecitabine\/temozolomide in metastatic neuroendocrine tumors. Oncologist 21, 671\u2013675 (2016).","journal-title":"Oncologist"},{"key":"86839_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cncr.25425","volume":"117","author":"JR Strosberg","year":"2011","unstructured":"Strosberg, J. R. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117, 268\u2013275 (2011).","journal-title":"Cancer"},{"key":"86839_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000500862","volume":"110","author":"L de Mestier","year":"2020","unstructured":"de Mestier, L. et al. Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor. Neuroendocrinology 110, 83\u201391 (2020).","journal-title":"Neuroendocrinology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86839-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:30:47Z","timestamp":1670049047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86839"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86839-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"14 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7881"}}